Evidence map›Paper›PMID 35163916›Full record

ArticleMolecules (Basel, Switzerland)2022

Mariafrancesca Hyeraci, Laura Agnarelli, Luca Labella, Fabio Marchetti, Maria Luisa Di Paolo, Simona Samaritani, Lisa Dalla Via

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mariafrancesca HyeraciDepartment of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy.
Laura AgnarelliDepartment of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, 56124 Pisa, Italy.
Luca LabellaDepartment of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, 56124 Pisa, Italy.ORCID 0000-0001-5001-7853
Fabio MarchettiDepartment of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, 56124 Pisa, Italy.
Maria Luisa Di PaoloDepartment of Molecular Medicine, Università degli Studi di Padova, Via G. Colombo 3, 35131 Padova, Italy.ORCID 0000-0002-2370-9333
Simona SamaritaniDepartment of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, 56124 Pisa, Italy.ORCID 0000-0002-3518-3164
Lisa Dalla ViaDepartment of Pharmaceutical and Pharmacological Sciences, Università degli Studi di Padova, Via F. Marzolo 5, 35131 Padova, Italy.ORCID 0000-0002-9828-9388
University of Pisa · ITUniversity of Padua · IT

Funding

Dipartimento di Scienze del Farmaco-Università di Padova PRID 2017 (DALL_SID17_02)Pisa University 2020-PRA_2020_39
6 · The paper itself

Abstract

The high incidence of the resistance phenomenon represents one of the most important limitations to the clinical usefulness of cisplatin as an anticancer drug. Notwithstanding the considerable efforts to solve this problem, the circumvention of cisplatin resistance remains a challenge in the treatment of cancer. In this work, the synthesis and characterization of two

Indexed as

Antineoplastic AgentsOvarian NeoplasmsCisplatinHumansOrganoplatinum CompoundsPlatinumAntineoplastic AgentsCisplatinOrganoplatinum CompoundsPlatinumantiproliferative activitydrug resistanceorganometallic complexesplatinum

Identifiers

PMID35163916
PMCPMC8838190
OpenAlexW4205564990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.